News | April 30, 2021
Indian vaccine players to garner Rs. 70,599 Cr in 2021
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
New manufacturing complex will occupy an overall footprint of approximately 2,000 square meter with six levels of manufacturing space
In animal health, the products will be mainly targeting mastitis and production disorders, gastrointestinal tract diseases, reproductive disorders, ectoparasites, and skin injuries
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The company also plans to register the similar range of products in the neighbouring countries.
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Presently, IMPCL is manufacturing 656 classical Ayurvedic, 332 Unani and 71 proprietary Ayurvedic medicines for the various diseases spectrum
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Subscribe To Our Newsletter & Stay Updated
